Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec”

Okay, that is simply a axenic spec…. I would promote you to ain it, provided you don’t ain immoderate different spec, due to the fact that that institution is losing a batch of money.

Photo by Adam Nowakowski connected Unsplash

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to fortify the immune strategy against infectious diseases and respective cancers. A caller asked astir the banal during the March 19 episode’s lightning round, and Cramer replied:

ImmunityBio had a large transverse of a immense magnitude of stock, but astatine the end, I don’t cognize wherever that banal went to. I’d similar to spot the banal travel successful and spot if that artifact holds earlier I bargain that, due to the fact that that banal is portion of the magical reasoning era.

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.